CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Alkermes rises on phase 1 results for ADHD drug ALKS 7290

Phase 1positiveALKS 7290Positive
AI Analysis

Summary

Alkermes reported positive Phase 1 results for ALKS 7290, its investigational ADHD drug candidate. The company's stock rose on the clinical progress announcement.

Clinical Trial Data

Phase

1

Importance:5/10
Sentiment:
0.60
Phase 1ADHDclinical trialpositive data
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on September 21, 2026 12:58 PM

Read Original